In late 2021, Johnson & Johnson announced plans to separate its consumer health division from its pharmaceutical and medical device divisions.
November 03, 2025
high
corporate
Corporate restructuring announcement to create an independent consumer health business.
Kenvue separated from Johnson & Johnson in 2023.
January 01, 2023
high
corporate
Corporate divestiture of a consumer health business.
Kenvue was spun off from Johnson & Johnson in 2023.
2023
high
general
Corporate restructuring and spin-off history.
Johnson & Johnson agreed in 2022 to pay $5 billion as part of a settlement addressing claims about the company's role in the opioid crisis.
January 01, 2022
high
temporal
Monetary settlement by a pharmaceutical company related to opioid litigation.
In 2021, Johnson & Johnson announced it would separate its consumer health business into a new company now known as Kenvue, and Kenvue owns the rights and liabilities associated with the sale of those over-the-counter products, including Tylenol.
January 01, 2021
high
temporal
Corporate restructuring and assignment of product rights/liabilities.